Inhaled budesonide in the treatment of early Covid-19 illness: A randomised controlled trial

Background Multiple early hospital cohorts of coronavirus disease 2019 (COVID-19) showed that patients with chronic respiratory disease were significantly under-represented. We hypothesised that the widespread use of inhaled glucocorticoids was responsible for this finding and tested if inhaled glucorticoids would be an effective treatment for early COVID-19 illness.

Methods We conducted a randomised, open label trial of inhaled budesonide, compared to usual care, in adults within 7 days of the onset of mild Covid-19 symptoms. The primary end point was COVID-19-related urgent care visit, emergency department assessment or hospitalisation. The trial was stopped early after independent statistical review concluded that study outcome would not change with further participant enrolment.

Results 146 patients underwent randomisation. For the per protocol population (n=139), the primary outcome occurred in 10 participants and 1 participant in the usual care and budesonide arms respectively (difference in proportion 0.131, p=0.004). The number needed to treat with inhaled budesonide to reduce COVID-19 deterioration was 8. Clinical recovery was 1 day shorter in the budesonide arm compared to the usual care arm (median of 7 days versus 8 days respectively, logrank test p=0.007). Proportion of days with a fever and proportion of participants with at least 1 day of fever was lower in the budesonide arm. Fewer participants randomised to budesonide had persistent symptoms at day 14 and day 28 compared to participants receiving usual care.

Conclusion Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery following early COVID-19 infection.

Evidence before this study The majority of interventions studied for the COVID-19 pandemic are focused on hospitalised patients. Widely available and broadly relevant interventions for mild COVID-19 are urgently needed.

Added value of this study In this open label randomised controlled trial, inhaled budesonide, when given to adults with early COVID-19 illness, reduces the likelihood of requiring urgent care, emergency department consultation or hospitalisation. There was also a quicker resolution of fever, a known poor prognostic marker in COVID-19 and a faster self-reported and questionnaire reported symptom resolution. There were fewer participants with persistent COVID-19 symptoms at 14 and 28 days after budesonide therapy compared to usual care.

Implications of all the available evidence The STOIC trial potentially provides the first easily accessible effective intervention in early COVID-19. By assessing health care resource utilisation, the study provides an exciting option to help with the worldwide pressure on health care systems due to the COVID-19 pandemic. Data from this study also suggests a potentially effective treatment to prevent the long term morbidity from persistent COVID-19 symptoms.

Read here (Medrxiv, Feb 8, 2021)

Ivermectin may not be the ‘silver bullet’ antiviral against Covid-19 (link to original Medrxiv report included)

‘A team of researchers based in Peru and the US recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19. The team has released their findings on the medRxiv preprint server... (link below).

Study details

‘The researchers included 12 qualitative and five quantitative studies, mostly preprints. These studies originated from all over the world, two being from the U.S., two from Spain, two from South America, one each from Iraq and Iran, and four from Bangladesh.

‘Altogether, there were around 7,400 participants, with a mean age of 47.5 years. About 60% were male. The treatment protocols for all included studies comprised ivermectin either alone or in combination with another anti-inflammatory, antibiotic or blood-thinning drug like azithromycin, hydroxychloroquine, dexamethasone, enoxaparin, aspirin or dicloxacillin...

‘Ivermectin was not significantly associated with a lower mortality or higher recovery of patients in this meta-analysis. However, the majority of studies were preprints, allowing for later changes in the data on which these conclusions are based.’

Read here (Medical News, Feb 1, 2021)

• Outcomes of Ivermectin in the treatment of COVID-19: A systematic review and meta-analysis

Read original study here (Medrxiv, Jan 27, 2021) 

More than 50 long-term effects of Covid-19: A systematic review and meta-analysis

‘COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers. This systematic review and meta-analysis aims to identify studies assessing long-term effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. All articles with original data for detecting long-term COVID-19 published before 1st of January 2021 and with a minimum of 100 patients were included. 

‘For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. Heterogeneity was assessed using I2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. 

‘The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. The follow-up time ranged from 15 to 110 days post-viral infection. The age of the study participants ranged between 17 and 87 years. It was estimated that 80% (95% CI 65-92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). All meta-analyses showed medium (n=2) to high heterogeneity (n=13). In order to have a better understanding, future studies need to stratify by sex, age, previous comorbidities, severity of COVID-19 (ranging from asymptomatic to severe), and duration of each symptom. From the clinical perspective, multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.’

Read/download PDF here (Medxiv, Jan 27, 2021)

Efficacy of colchicine in non-hospitalized patients with Covid-19 (pre-print)

Background Evidence suggests the role of an inflammatory storm in COVID-19 complications. Colchicine is an orally administered, anti-inflammatory medication beneficial in gout, pericarditis and coronary disease.

Methods We performed a randomized, double-blind trial involving non-hospitalized patients with COVID-19 diagnosed by polymerase chain reaction (PCR) testing or clinical criteria. The patients were randomly assigned to receive colchicine (0.5 mg twice daily for 3 days and once daily thereafter) or placebo for 30 days. The primary efficacy endpoint was the composite of death or hospitalization for COVID-19.

Results A total of 4488 patients were enrolled. The primary endpoint occurred in 4.7% of the patients in the colchicine group and 5.8% of those in the placebo group (odds ratio, 0.79; 95.1% confidence interval (CI), 0.61 to 1.03; P=0.08). Among the 4159 patients with PCR-confirmed COVID-19, the primary endpoint occurred in 4.6% and 6.0% of patients in the colchicine and placebo groups, respectively (odds ratio, 0.75; 95% CI, 0.57 to 0.99; P=0.04). In these patients with PCR-confirmed COVID-19, the odds ratios were 0.75 (95% CI, 0.57 to 0.99) for hospitalization due to COVID-19, 0.50 (95% CI, 0.23 to 1.07) for mechanical ventilation, and 0.56 (95% CI, 0.19 to 1.66) for death. Serious adverse events were reported in 4.9% and 6.3% in the colchicine and placebo groups (P=0.05); pneumonia occurred in 2.9% and 4.1% of patients (P=0.02). Diarrhea was reported in 13.7% and 7.3% in the colchicine and placebo groups (P<0.0001).

Conclusion Among non-hospitalized patients with COVID-19, colchicine reduces the composite rate of death or hospitalization. (COLCORONA ClinicalTrials.gov number: NCT04322682)

Read here (Medrxiv, Jan 26, 2021)

Viral loads: Review points to PCR-testing inadequacies and need to prioritise early case detection

A review of 79 studies on viral loads in people — specifically, SARS-CoV-2, SARS-CoV-1 and MERS-CoV — has shown that (1) ‘viral RNA can persist in and be shed from the body for long periods of time (more than 80 days in some cases)’ although ‘SARS-CoV-2 only remains viable and infectious for approximately one week after the onset of symptoms’ (2) ‘Viral load was at its highest approximately 3-5 days after the onset of symptoms, and there was a positive correlation between prolonged viral shedding and disease severity. Older patients also experienced prolonged viral shedding compared to younger patients, even when accounting for disease severity...

‘While there are fewer studies on the kinetics of viral load for asymptomatic infections, viral shedding appeared to be of a shorter duration, and overall viral load appeared to be lower compared to symptomatic cases.’ 

The authors conclude that (1) ‘PCR testing is likely not a good tool for evaluating patient recovery, because viral RNA is detectable long after the end of the infectious period’. (2) ‘Early case detection and isolation should be prioritised in order to maximise control efforts during the time when patients are the most infectious.’ -- Center for Health Security, John Hopkins University

https://www.medrxiv.org/content/10.1101/2020.07.25.20162107v2.full.pdf

Read here (Medrxiv, July 25, 2020)

Antibody tests don't mean a ton right now. But that could change soon

‘In the study published in medRxiv, a preprint server for posting studies before they are peer-reviewed, a team at the Lindsley F. Kimball Research Institute of the New York Blood Center and Rockefeller University analyzed 370 plasma samples donated from people who recovered from COVID-19 and found some surprising results...

‘Overall, around 88% of the people generated varying levels of antibodies to the virus. But only about 10% of them had high levels that were able to neutralize the lab-based version of the COVID-19 virus—and, on the other side of the spectrum, 17% had almost no antibody response to their infection.’

Read here (Time Magazine, June 16, 2020)

Can gut microbes predict Covid-19 severity?

‘COVID-19 is notorious for striking harder at older patients, often landing them in bed, hooked up to a ventilator. Once that happens, the odds get grim: according to one report, only one in seven intubated patients survived. No one knows exactly why some patients are affected more than others, but a new study from China (that has not yet been peer-reviewed) makes a provocative assertion: the health of the gut microbiome may predict the severity of the disease. The healthier the gut, the better the outcome. That may be something to cheer about, because you can improve your microbiome in a matter of days just by changing your diet. It could save your life.’

Read here (Psychology Today, May 1, 2020) and here (Medrxiv, April 25, 2020)

‘SARS-CoV-2 RNA found in air pollution particles in Italy’

’A study conducted in Italy (not yet peer reviewed) detected the presence of SARS-CoV-2 RNA in air pollution particles. The particulate matter that contributes to air pollution can be inhaled, potentially providing an additional mechanism for SARS-CoV-2 infection. This study did not evaluate the viability of the virus detected in the air pollution, nor did it assess the potential for this route of exposure to result in infection.‘

Read here (Medrxiv, April 15, 2020)

Nations with mandatory TB vaccines show fewer coronavirus deaths

‘The preliminary study posted on medRxiv, a site for unpublished medical research, finds a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from Covid-19. Though only a correlation, clinicians in at least six countries are running trials that involve giving frontline health workers and elderly people the BCG vaccine to see whether it can indeed provide some level of protection against the new coronavirus.’

Read here (Bloomberg, April 2, 2020)

Modes of contact and risk of transmission in COVID-19 among close contacts

A new preprint on medRxiv examines the modes of contact and the level of transmission among close contacts of persons infected with COVID-19. The study follows just under 5,000 close contacts in Guangzhou, China. Of the close contacts identified, 2.6% of cases developed symptoms during their quarantine, the majority of which were mild or moderate cases (89.9%) and a small portion of which were asymptomatic (6.2%). They authors found that contacts within the same household were at the highest risk of contracting COVID-19.

Read here (Medrxiv, March 26, 2020)

Note: As the Covid-19 situation worsens in the US, Europe and other countries, our students and other citizens are coming home in large numbers. They are being told to self-quarantine. Many are doing it at home, in which case they may infect others if they are carrying the virus. Some are sending their folks to AirBNBs.